Not Yet RecruitingNot Applicable

A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates

500 participantsStarted 2026-04-01

Plain-language summary

The aim of this study is to evaluate the real-world effectiveness of ARNi (sacubitril/valsartan) therapy and standard antihypertensive monotherapy in reducing blood pressure in hypertensive patients residing in the United Arab Emirates. Standard antihypertensive monotherapies will include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and calcium channel blockers (CCBs).

Who can participate

Age range18 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adult male or female patients (≥18 years).
✓. Patients with physician-diagnosed hypertension (as defined by the American Heart Association/American College of Cardiology international guidelines).
✓. Patients who are either antihypertensive therapy naïve or currently receiving antihypertensive monotherapy (ACE inhibitor/ARB/CCB) with a physician-directed requirement to transition to ARNi.
✓. Patients willing to provide written informed consent to participate in the study.

Exclusion criteria

✕. Patients with malignant or severe hypertension (systolic blood pressure \[SBP\] ≥180 mmHg, diastolic blood pressure \[DBP\] ≥110 mmHg) at baseline.
✕. Patients with secondary causes of hypertension, as determined by the treating physician.
✕. Patients with a history of, or at risk of developing, angioedema.
✕. Patients with evidence of severe renal impairment (e.g., estimated glomerular filtration rate \[eGFR\] \<30 mL/min/1.73 m\^2).
✕. Pregnant or lactating women.
✕. Patients with serum potassium level ≥5.5 mmol/L at baseline.

What they're measuring

Change From Baseline to Week 4 in Mean Sitting SBP

Timeframe: Baseline to Week 4

Trial details

NCT IDNCT07465666

SponsorNovartis Pharmaceuticals

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2027-04-18

Contact for this trial

Novartis Pharmaceuticals

+41613241111 novartis.email@novartis.com

View on ClinicalTrials.gov More Hypertension trials